John Buse is Verne S Caviness Distinguished Professor of Medicine and Senior Associate Dean for Clinical Research at the University of North Carolina, as well as Director of the University of North Carolina Diabetes Care Center and Director of the North Carolina Translational and Clinical Sciences Institute. He received his medical degree and PhD from Duke University, USA, before training in internal medicine and endocrinology at the University of Chicago.

His practice combines clinical care, research and education and he practises patient-centred care that focuses on developing treatment programmes in collaboration with patients. He has received international recognition for innovative clinical care and efforts at prevention of type 1 and type 2 diabetes and their complications.

He also works with teams of investigators in diabetes clinical trials, comparative effectiveness research and translation of basic science research towards clinical application. Current projects are focused on novel treatments, including development of glucose-responsive insulin, cardiovascular safety and efficacy of diabetes drugs, and developing the evidence-base for treatment guidelines of the future in diabetes care. He co-chaired the ACCORD trial and chaired the LEADER trial.

Professor Buse served as President for Medicine and Science at the American Diabetes Association in 2008 and as Chair of the National Diabetes Education Program in 2014. He has authored more than 500 publications.

Duality of interest: Professor Buse has received research support grants from Bayer, Boehringer-Ingelheim, Carmot, Corcept, Dexcom, Eli Lilly, Insulet, MannKind, Novo Nordisk, and vTv Therapeutics. These are largely clinical trial contracts, whish are paid to the University of North Carolina. In addition salary support is received from grants from the National Institutes of Health. He also receives consultancy fees from Alkahest, Altimmune, Anji, Aqua Medical Inc, AstraZeneca, Bayer, Biomea Fusion Inc, Boehringer-Ingelheim, CeQur, Corcept Therapeutics, Dasman Diabetes Center (Kuwait), Eli Lilly, embecta, Fortress Biotech, GentiBio, Glycadia, Glyscend, Janssen, MannKind, Mediflix, Medscape, Mellitus Health, Metsera, Moderna, Pendulum Therapeutics, Praetego, ReachMD, Sanofi, Stability Health, Tandem, Terns Inc, Valo and Zealand Pharma together with contracted consulting fees and travel support for contracted activities from Novo Nordisk which are paid to the University of North Carolina; which provide no direct financial benefit to him.

Professor Buse also has stock/shares in Glyscend, Mellitus Health, Pendulum Therapeutics, PhaseBio, Praetego, and Stability Health together with payment for other positions or financial relationships from Medtronic MiniMed.  

Date: Autumn 2023